Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Car-t for paediatric all
A clinical guide for families exploring CAR-T cell therapy for paediatric acute lymphoblastic leukaemia (ALL). Learn how chimeric antigen receptor T-cell therapy works, candidate eligibility criteria, stepwise treatment stages from apheresis to infusion, remission rates and evidence, management of cytokine release syndrome, recovery milestones, and comparative costs across Turkey, the UK, US, and Germany.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for CAR-T for Paediatric ALL
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is CAR-T for paediatric ALL and how does it work?
CAR-T for paediatric ALL (chimeric antigen receptor T-cell therapy) is an advanced cellular immunotherapy for children and young adults with acute lymphoblastic leukaemia. When chemotherapy fails, CAR-T provides a targeted biological mechanism. A patient's own white blood cells (T-lymphocytes) are collected via leukapheresis and genetically modified in an accredited laboratory using an inactive viral vector. This reprogramming equips the cells to express synthetic receptors that bind to CD19, a protein found on malignant B-cells. Multiplied into millions of copies, the re-engineered cells are infused back into the child's bloodstream to detect and destroy leukaemia cells.
Because CAR-T functions as a living treatment that continues multiplying inside the body, it provides prolonged surveillance against leukemic recurrence. Specialised centres provide this treatment as part of comprehensive oncology treatments in Turkey. This guide explains how the therapy works, what clinical trials confirm, recovery timelines, safety risks, and approximate international costs.
How are CAR-T cells engineered and infused step by step?
The treatment pathway involves five structured stages coordinated across specialised clinical and laboratory teams:
- Assessment and workup: Comprehensive bone marrow examinations, lumbar punctures, imaging, and organ function tests verify eligibility and baseline health.
- Leukapheresis (harvesting): Blood passes through an apheresis machine via a central line to separate T-lymphocytes, returning remaining blood components. This takes three to five hours.
- Cell reprogramming: An accredited laboratory inserts the chimeric receptor gene and expands the modified cells over two to four weeks. During this period, interim bridging therapies, including low-dose chemotherapy, may control blast counts.
- Lymphodepleting conditioning: Two to three days of pre-infusion chemotherapy (typically fludarabine and cyclophosphamide) clear existing lymphocytes, creating biological space for the new cells to multiply.
- Infusion: Following a rest period, engineered cells are administered intravenously over 30 to 60 minutes under close vital-sign monitoring.
The child is then admitted for continuous inpatient observation in a protective oncology ward.
Does CAR-T for paediatric ALL actually work? What clinical evidence shows
Clinical trials confirm that CAR-T for paediatric ALL is highly effective for patients whose B-cell leukaemia has relapsed or resisted prior regimens. Pivotal trials, such as the ELIANA study evaluated by international health authorities, demonstrated complete remission rates of 80% to 85% within three months of infusion. Many patients achieved minimal residual disease (MRD) negative remission, meaning sensitive molecular diagnostics detected no residual leukaemia cells in the bone marrow.
However, CAR-T is not a universal cure. Follow-up research indicates that approximately 40% to 50% of children experience disease recurrence within one to two years. Relapse occurs mainly through loss of the target antigen (CD19-negative escape) or exhaustion and disappearance of the circulating CAR-T cells. Medical teams monitor persistence closely to evaluate whether consolidative allogeneic stem cell transplantation is indicated.
Who is an eligible candidate for paediatric CAR-T therapy?
Candidate selection is governed by international haematology guidelines to ensure safe, appropriate application:
- Confirmed B-ALL diagnosis: Children and young adults up to 25 years with CD19-positive B-cell leukaemia that is refractory, in second or later relapse, or recurring post-transplant.
- Organ function: Adequate cardiac, kidney, and lung performance to withstand temporary inflammatory stress.
- Controlled tumour burden: While high-burden disease can be treated, pre-infusion bridging reduces blast counts to minimise toxicity.
Patients are ineligible if their leukaemia lacks CD19 expression, if they have active, uncontrolled systemic infections, or if they suffer severe multi-organ failure. Severe active graft-versus-host disease (GvHD) from an earlier transplant must also resolve before starting therapy.
CAR-T for paediatric ALL cost in Turkey compared with the UK, US and Germany
Cellular therapies involve bespoke laboratory bioengineering and dedicated hospital infrastructure. The figures below reflect broad approximate ranges for full medical packages, including cell processing, conditioning, hospitalisation, and initial acute complication management.
| Country | Approximate cost range |
|---|---|
| Turkey | €60,000 – €140,000 |
| United Kingdom | €320,000 – €500,000 |
| United States | €450,000 – €950,000 |
| Germany | €300,000 – €480,000 |
Price differences reflect cell sourcing (point-of-care academic manufacturing versus commercial brand-name constructs), duration of paediatric intensive care unit (PICU) stays, and requirement for supportive medications like tocilizumab or immunoglobulins. Packages generally include consultations, apheresis, bioengineering, conditioning, infusion, hospital stays, and immediate monitoring. Request a written itemised quote before travelling.
CAR-T cell therapy, allogeneic stem cell transplant or targeted immunotherapy?
When acute lymphoblastic leukaemia relapses, clinical teams compare CAR-T against alternative cellular treatments and immunotherapy options to determine the most effective strategy.
| Approach | Best suited to | Typical limits |
|---|---|---|
| CAR-T cell therapy | Relapsed or refractory CD19+ B-ALL after chemotherapy or prior transplant | High upfront cost; requires cell manufacturing time; risk of CRS and neurotoxicity |
| Allogeneic stem cell transplant (Allo-HSCT) | High-risk ALL in first or subsequent remission with an available donor | Requires a matched donor; graft-versus-host disease (GvHD); high non-relapse mortality |
| Targeted bispecific immunotherapy | Minimal residual disease (MRD) clearance or bridging to transplant/CAR-T | Continuous intravenous infusion over weeks; less durable as standalone monotherapy |
While allogeneic transplantation replaces the bone marrow and establishes donor immunity, it carries substantial risk of graft-versus-host disease. Bispecific antibodies and monoclonal targeted therapy provide precise tumour debulking but show lower standalone durability in advanced relapse. Teams select therapies based on disease kinetics and prior interventions.
What does remission look like? Understanding results after CAR-T infusion
In leukaemia treatment, "before and after" assessments are biological rather than physical. Clinical success is measured through bone marrow examinations performed approximately 28 days following infusion.
Complete morphological remission requires fewer than 5% blast cells in marrow alongside recovering peripheral blood counts. Highly sensitive flow cytometry or molecular assays then test for minimal residual disease (MRD). Achieving MRD negativity—zero detectable leukemic cells among one million marrow cells—correlates strongly with prolonged event-free survival. The ongoing presence of B-cell aplasia (the absence of normal B-lymphocytes) indicates that functional CAR-T cells persist in the body, continuing immune surveillance.
Treatment timeline and recovery: staying in Turkey for paediatric CAR-T
Families travelling to Turkey should plan for an overall stay of six to ten weeks. Treatment progresses through distinct phases:
- Weeks 1–2 (Evaluation & harvesting): Workup, central line placement, and leukapheresis cell collection. Bridging therapy may proceed as an outpatient.
- Weeks 3–4 (Conditioning & infusion): Inpatient admission to an isolation suite for lymphodepleting chemotherapy, rest days, and cellular infusion.
- Weeks 5–6 (Inpatient monitoring): Dedicated observation for acute inflammatory complications and neurotoxicity, with continuous vital signs and neurological checks.
- Weeks 7–10 (Marrow assessment & travel clearance): A day-28 bone marrow biopsy confirms remission. Once blood counts stabilize and no active toxicities persist, the child receives flight clearance.
Full immune recovery requires six to twelve months of outpatient care, including infection prophylaxis and routine paediatric follow-up.
Risks and complications: managing CRS and neurotoxicity
Cellular therapy carries significant acute risks established in reports by the European Medicines Agency (EMA) and United States FDA:
- Cytokine Release Syndrome (CRS): Massive immune cell activation releases inflammatory cytokines, causing high fevers, low blood pressure, and breathing difficulty. Teams manage CRS with oxygen, IV fluids, and anti-IL-6 therapy (tocilizumab), reserving corticosteroids for higher grades.
- Neurotoxicity (ICANS): Immune-related neurological events produce confusion, speech disturbance, tremor, or somnolence. Regular cognitive monitoring detects onset early, treated with systemic corticosteroids.
- Cytopenias and infection: Prolonged low blood cell counts require blood transfusions and antibiotic coverage.
- B-cell aplasia: Destruction of normal B-cells causes hypogammaglobulinaemia, requiring monthly intravenous immunoglobulin (IVIG) infusions to maintain infection resistance.
How to choose a paediatric oncology centre and questions to ask the medical team
Cellular therapies should only be undertaken in tertiary paediatric hospitals holding international healthcare accreditation (such as JCI) and JACIE cellular therapy certification. Essential criteria include an on-site, 24-hour Paediatric Intensive Care Unit (PICU), experienced paediatric haematologists, and immediate stock of emergency medications like tocilizumab.
Review how our process works to understand international coordination, and submit medical records for review through our free quote portal. Key questions for the clinical team include:
- How many paediatric CAR-T procedures has your clinical team performed?
- Is the cell therapy commercially licensed or manufactured in an accredited point-of-care laboratory?
- What protocols and on-site PICU coverage exist for managing severe CRS and ICANS?
- Are ICU stays and emergency drugs like tocilizumab covered in the fixed estimate?
- What bridging chemotherapy will the child receive during cell processing?
- How will your team communicate with our home haematologist after discharge?
Hospitals with Oncology in Turkey
Frequently asked questions
CAR-T for paediatric ALL is an advanced form of cell-based immunotherapy for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. The child's own T-lymphocytes are harvested, genetically modified in an accredited laboratory to express chimeric antigen receptors targeting CD19 proteins on leukaemia cells, multiplied, and re-infused into the bloodstream.
Clinical studies, including pivotal trials reviewed by international regulatory agencies, show complete remission rates between 80% and 85% within three months of infusion in patients whose leukaemia had returned or failed prior therapies. However, long-term remission depends on CAR-T cell persistence, and around 40% to 50% of children may eventually experience disease recurrence.
The approximate cost of CAR-T cell therapy in Turkey ranges from €60,000 to €140,000. This is substantially lower than in the UK (€320,000 to €500,000) or the US (€450,000 to €950,000). The total price depends on cell manufacturing logistics, bridging chemotherapy, inpatient length of stay, and intensive care supportive medications.
In leukaemia care, 'before and after' refers to disease clearance rather than physical appearance. Before therapy, children show persistent blast cells in their bone marrow. After infusion, doctors assess response at day 28 using flow cytometry and molecular tests to confirm complete morphological remission and minimal residual disease (MRD) negative status.
Neither treatment is universally superior. CAR-T therapy is specifically designed for CD19-positive leukaemia that has resisted standard treatments or relapsed after a prior stem cell transplant. For some patients, CAR-T achieves deep remission that serves as a bridge to a subsequent allogeneic transplant, while others remain in durable remission without further procedures.
Acute hospital recovery takes approximately four to six weeks. This period covers lymphodepleting conditioning, cell infusion, and close inpatient observation for cytokine release syndrome or neurological side effects. Full immune reconstitution and recovery of normal blood cell production typically take six to twelve months, during which prophylactic antibiotics and immunoglobulin support continue.
The intravenous infusion itself is painless and resembles a routine blood transfusion, taking 30 to 60 minutes. Discomfort primarily arises during leukapheresis catheter placement and from expected inflammatory side effects in the days following infusion, such as high fevers, fatigue, muscle aches, or temporary low blood counts, all managed with supportive medical care.
Many children remain in prolonged remission for years after a single infusion. Long-term durability relies on functional CAR-T cells remaining in the body or the successful eradication of all leukemic clones. Relapses can occur if modified cells stop circulating or if leukaemia cells mutate to lose the target CD19 surface protein.
The most significant acute risks are cytokine release syndrome (CRS), caused by rapid immune system activation, and immune effector cell-associated neurotoxicity syndrome (ICANS). Both conditions require immediate intervention in a specialised paediatric hospital with tocilizumab and corticosteroids. Long-term effects include prolonged B-cell aplasia, requiring regular intravenous immunoglobulin infusions.
Families generally spend between six and ten weeks in Turkey. This timeframe accommodates baseline oncological evaluation, T-cell harvesting via apheresis, interim bridging therapy while cells are processed, lymphodepleting chemotherapy, the infusion, and at least four weeks of mandatory post-infusion monitoring before travel clearance is safely granted.
Patient stories